On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize a pseudovirus bearing the SARS-CoV-2 U.K. variant, also known as B.1.1.7 lineage, were published in the journal Science.

The study included a larger number of sera from vaccinated individuals and confirms the initial study results that the B.1.1.7 lineage is unlikely to escape BNT162b2-mediated protection.